Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a sterile intravenous solution for intravenous use. It provides passive immunity by supplying pooled IgG antibodies and is employed in the management of various primary and secondary immune deficiencies as well as certain autoimmune and inflammatory disorders.

GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance, cold‑chain logistics and regulatory compliance for all shipments.

Iqymune is used in immune‑mediated conditions where replacement or modulation of IgG antibodies is required.

Primary immunodeficiency diseases: restores deficient IgG levels, reducing infection frequency and severity. Secondary immunodeficiency (e.g., chemotherapy, HIV): provides passive immunity to protect against opportunistic infections. Immune thrombocytopenic purpura: modulates immune response to increase platelet count and reduce bleeding risk. Kawasaki disease: attenuates vascular inflammation and lowers risk of coronary artery complications. Multifocal motor neuropathy: supplies antibodies that improve nerve conduction and muscle strength.

Administration of Iqymune may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache during or after infusion. - Fever: transient rise in body temperature. - Chills or rigors: shaking sensations commonly occurring with infusion. - Nausea: mild gastrointestinal upset. - Fatigue: feeling of tiredness post‑infusion. - Back pain: discomfort at infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Thromboembolic events: clot formation that can lead to vascular occlusion. - Renal impairment: acute kidney injury manifested by reduced urine output or elevated creatinine. - Aseptic meningitis: inflammation of meninges without infection.

Prior to prescribing Iqymune, clinicians should consider several precautionary measures to ensure patient safety. - Assess immunoglobulin levels: confirm deficiency or indication before therapy. - Monitor for infusion reactions: observe patient during and after administration. - Screen for renal function: evaluate baseline creatinine and adjust if impaired. - Evaluate thrombotic risk: consider history of clotting disorders before infusion. - Avoid in patients with IgA deficiency and anti‑IgA antibodies: risk of severe anaphylaxis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iqymune can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may reduce vaccine efficacy or increase risk. - High‑dose aspirin or NSAIDs: may increase bleeding risk during infusion.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclophosphamide, rituximab): may alter immune response, require dose adjustment. - Diuretics: potential for volume overload; monitor fluid status. - Anticoagulants (e.g., warfarin): may affect coag